Lundbeck to expand opportunities in Canada and Latin America with Cephalon products

10 February 2011

Danish drugmaker Lundbeck A/S (LUND: DC) says it has been granted commercial rights to several products from US firm Cephalon (Nasdaq: CEPH) in Canada and Latin America. As part of the agreement, Lundbeck will register and commercialize several key products which are currently available in the USA and/or Europe on behalf of Cephalon.

Financial terms of the agreement have not been disclosed, but Lundbeck is to pay double-digit royalties on sales which will be the main overall revenue stream for Cephalon from these products in these territories, the company stated.

Key products in the agreement include Fentora (fentanyl buccal tablet) [C-II], Provigil (modafinil), Treanda (bendamustine hydrochloride), Trisenox (arsenic trioxide) injection, Myocet (liposomal- doxorubicin) and Nuvigil (armodafinil).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK